Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00238628 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
A Phase 1 study of Lung Cancer, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00238628: Completed Phase 1 study of Lung Cancer, sponsored by Stanford University.
NCT00238628 is a Phase 1 study of Lung Cancer that has completed, run by Stanford University. The registered enrollment target is 12 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00238628, a Phase 1 study of Lung Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
Conditions Studied
Interventions
- DRUG Bexarotene
- DRUG Iressa
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00238628
The ClinicalTrials.gov registry entry for NCT00238628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bexarotene is the first listed.
NCT00238628 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00238628 about?
NCT00238628 is a clinical study titled "A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer". The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
What is the current status of trial NCT00238628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-04. Estimated completion is 2005-12.
What conditions does trial NCT00238628 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00238628?
The interventions under investigation include: Bexarotene (DRUG), Iressa (DRUG).
Who is sponsoring clinical trial NCT00238628?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00238628 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.